|
|
Article: Curis Announces Phase II Clinical Plan for Hedgehog Antagonist Presented by Collaborator Genentech.
- Article from:
- Business Wire
- Article date:
- March 14, 2008
|
Copyright informationCOPYRIGHT 2008 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Genentech indicates that it expects to initiate three Phase II clinical trials of GDC-0449 in 2008
CAMBRIDGE, Mass. -- Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing novel targeted medicines primarily for cancer treatment, today announced that its collaborator Genentech provided an update on its Phase II clinical trial plans for GDC-0449. GDC-0449 is an orally-administered small molecule antagonist of Hedgehog signaling and is being developed pursuant to the parties' June 2003 collaboration agreement. Genentech also announced that it has seen partial responses in advanced basal cell carcinoma tumors in the ongoing Phase I clinical trial of ...